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C A N C E R
Topography of transcriptionally active  
chromatin in glioblastoma
Liang Xu1,2*†‡, Ye Chen1*†, Yulun Huang3,4,5†, Edwin Sandanaraj6,7, John S. Yu8,  
Ruby Yu-Tong Lin1, Pushkar Dakle1, Xin-Yu Ke1, Yuk Kien Chong6, Lynnette Koh6,9, 
Anand Mayakonda1, Kassoum Nacro10, Jeffrey Hill11, Mo-Li Huang1,12, Sigal Gery13,  
See Wee Lim6, Zhengyun Huang14, Ying Xu14, Jianxiang Chen15,16,17, Longchuan Bai18,19, 
Shaomeng Wang18,19,20,21, Hiroaki Wakimoto22, Tseng Tsai Yeo23, Beng Ti Ang24,25,  
Markus Müschen26,27, Carol Tang6,9,28, Tuan Zea Tan1*, H. Phillip Koeffler1,13,23
Molecular profiling of the most aggressive brain tumor glioblastoma (GBM) on the basis of gene expression, DNA 
methylation, and genomic variations advances both cancer research and clinical diagnosis. The enhancer ar-
chitectures and regulatory circuitries governing tumor-intrinsic transcriptional diversity and subtype identity are 
still elusive. Here, by mapping H3K27ac deposition, we analyze the active regulatory landscapes across 95 GBM 
biopsies, 12 normal brain tissues, and 38 cell line counterparts. Analyses of differentially regulated enhancers and 
super-enhancers uncovered previously unrecognized layers of intertumor heterogeneity. Integrative analysis of 
variant enhancer loci and transcriptome identified topographies of transcriptional enhancers and core regulato-
ry circuitries in four molecular subtypes of primary tumors: AC1-mesenchymal, AC1-classical, AC2- proneural, 
and AC3-proneural. Moreover, this study reveals core oncogenic dependency on super-enhancer–driven transcrip-
tional factors, long noncoding RNAs, and druggable targets in GBM. Through profiling of transcriptional en-
hancers, we provide clinically relevant insights into molecular classification, pathogenesis, and therapeutic 
intervention of GBM.
INTRODUCTION
Glioblastoma (GBM) is the deadliest and most devastating brain 
cancer in adults (1). Despite aggressive multimodality treatment of 
maximal surgical resection, radiation, chemotherapy with temo-
zolomide (TMZ), and adjuvant tumor-treating fields, tumor recur-
rence is nearly universal, and patient survival remains dismal (2–4). 
Thus, an urgent need exists to advance the molecular understanding 
of GBM and develop innovative diagnostic or therapeutic approaches 
to combat this lethal disease.
Multiomics characterization by The Cancer Genome Atlas Re-
search Network (TCGA) has revealed biologically relevant alterations 
and pathways across GBM samples and subsequently guided the 
molecular classification of this heterogeneous disease (5–8). Tran-
scriptional classification of bulk GBM has greatly improved the un-
derstanding of molecular pathobiology. Transcriptional subtypes 
demonstrate close association with prognosis, therapeutic response, 
genomic insults, and tumor microenvironment (8–10). One preva-
lent classification scheme that is based on unsupervised clustering 
of bulk tumor transcriptome involves four subtypes, namely, mes-
enchymal (MES), classical (CL), neural, and proneural (PN) (8). 
Further, by using GBM-intrinsic gene expression (GIE) signature to 
reduce the transcriptional noise from GBM-associated stroma, 
classification of isocitrate dehydrogenase (IDH)–wild-type tumors 
is refined as three GIE subtypes (GIE-MES, GIE-CL, and GIE-PN) (9). 
GIE subtypes reflect heterogeneous compositions of GBM cells in 
distinct states among bulk tumors (11). At the single-cell level, four 
cellular states have been identified in GBM cells, resembling neural 
progenitors, oligodendrocyte progenitors, astrocytes, and MES cells, 
respectively (11). Although genomic defects such as aberrations in 
cyclin-dependent kinase 4 (CDK4), platelet-derived growth factor 
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receptor alpha (PDGFRA), epidermal growth factor receptor (EGFR), 
and neurofibromin 1 (NF1) have been shown to favor the development 
of individual cellular states and transcriptional subtypes, epigenetic 
mechanisms governing transcriptional diversity among GBM subtypes 
stay largely unknown. Besides, the regulatory networks that dictate 
GBM identity and malignant traits remain inadequately addressed.
Active regulatory elements (AREs), especially enhancers and 
large clustered enhancers [known as super-enhancers (SEs)] (12), 
recruit sequence-specific transcription factors (TFs), chromatin 
regulatory machinery, and transcriptional apparatus to regulate tis-
sue/disease-specific gene expression. As exemplified by application 
of DNA methylation signatures to fine-tune GBM molecular subtypes 
(6), integration of epigenetic chromatin information will provide 
critical insights into transcriptional heterogeneity and classifica-
tion. Seminal studies of GBM AREs mainly focused on ex vivo ex-
panded GBM cells, including patient-derived GBM-propagating 
cells (GPCs) (13–18), while tissue-centric analysis in the light of 
tissue complexity and tumor heterogeneity is still lacking. To this 
end, we performed in-depth chromatin immunoprecipitation fol-
lowed by massive parallel sequencing (ChIP-seq) analysis for H3K27ac, 
a histone modification to annotate regions of actively transcribed 
chromatin (19), in a large collection of samples comprising 95 GBM 
tissues, 1 oligoastrocytoma, 12 normal brain specimens, and 38 cell 
lines. Our efforts to build a comprehensive compendium of clinically 
relevant active regulatory regions in GBM facilitated discovery of 
tumor/subtype-related enhancer-gene regulation, identification of 
core TF circuitries, and exploration of previously unrecognized on-
cogenic addiction, thereby advancing the understanding of tran-
scriptional diversity and disease heterogeneity.
RESULTS
Characteristics of sample cohort and data availability
H3K27ac signals are deposited across transcriptionally active chro-
matin. To map genome-wide AREs in human GBM, we first ana-
lyzed the H3K27ac ChIP-seq profiles in a series of 50 fresh-frozen 
tumor specimens (49 GBM and a grade 3 oligoastrocytoma), 20 patient- 
derived GPCs, and 5 established GBM cell lines, together with a 
control set of samples including 12 normal brain tissues, 12 neural 
stem/progenitor cells (NPCs), and 1 line of primary human astro-
cytes [see detailed sample information in table S1 (A and B)] 
(14–18, 20–27). To facilitate transcriptional classification and de-
tection of disease-relevant mutations/aberrant transcripts, a cognate 
transcriptomic-sequencing [RNA sequencing (RNA-seq)] analysis 
was performed for 48 tumors (i.e., 47 GBM and a grade 3 oligoas-
trocytoma) and 3 normal brain tissues. Our discovery cohort of pri-
mary GBM specimens (defined as cohort 1) is inclusive of all three 
tumor-intrinsic gene expression subtypes (GIE-MES, n = 21; GIE-CL, 
n = 12; and GIE-PN, n = 14). Among those, 40 GBM cases (number 
of uniquely mapped RNA-seq reads, >15 million) were enrolled in 
the study of GBM/subtype-specific gene expression (table S1A).
Landscape of AREs in GBM
In total, 4,715,512 and 1,591,664 H3K27ac peaks were captured in 
the discovery cohort of tumor and nontumor tissues/cells, respec-
tively. These actively regulated regions were classified into either 
proximal promoters (containing 855,318 peaks) or putative enhancers 
(containing 5,451,858 peaks). More than 88% of promoter-associated 
H3K27ac peaks were conserved between normal/tumor brain and 
their respective cell line counterparts, while enhancer-associated 
signals showed greater variations (fig. S1A). Unsupervised hierar-
chical clustering of the top 5867 most-varying loci (mean, ≥10; me-
dian absolute deviation, >1) among our dataset (n = 100) revealed 
six discrete clusters (fig. S1, B to D, and table S1, A and B). The 
majority (47/50) of tumor tissue samples were classified into three 
clusters, one of which coenriched normal brain samples. About 
90% of cell line samples including established GBM cell lines, GPCs, 
NPCs, and primary astrocytes were classified into the other three 
clusters, while a few cell lines were also found in clusters that were 
mainly composed of either normal or tumor tissues (fig. S1D). In 
general, tissues samples and cell line samples showed a low degree 
of coclustering, highlighting the necessity of chromatin profiling of 
primary tumor biopsies to understand its dysregulation in the con-
text of complex tissue/tumor microenvironment.
To extend current knowledge of GBM chromatin, which is pri-
marily derived from cell line–based work, we next focused our analysis 
on primary tissues. To begin with, we performed a pairwise H3K27ac– 
to–RNA-seq data analysis across tissue samples in this study using 
either all detected H3K27ac sites or the signals pertaining to gene 
promoters. Both types of chromatin signals showed a stronger cor-
relation with the transcriptome from the corresponding sample 
(self) than that from other samples (fig. S1E), suggesting a robust 
sample concordance and no sample mix-ups. Our tissue-centric 
analysis then refined the clustering of GBM and normal brain sam-
ples using top-variant AREs (mean, ≥10; median absolute devia-
tion, >1; n = 1107) among them. On the basis of ARE consensus 
clustering, GBM samples in cohort 1 can be categorized into three 
groups, namely, AC1 (n  =  32), AC2 (n  =  8), and AC3 (n  =  9) 
(Fig. 1, A and B; fig. S1, F and G; and table S1A). The AC1 subclass 
included most of the GBM cases belonging to GIE-MES and GIE-CL, 
while more than 80% of GIE-PN tumor samples were classified into 
either AC2 or AC3. Convergence of “transcriptionally different” GIE-
MES and GIE-CL samples on AC1 subtype indicates (i) a relatively 
high degree of similarity in the top-variant H3K27ac loci between 
the two groups and (ii) a substantial remodeling of ARE topography, 
which separates them from normal brain and GIE-PN tumors.
Moreover, on the basis of the analysis of cohort 1, AC1 subtype 
showed higher microenvironment and stromal scores, male-to-female 
ratio, and alterations in telomerase reverse transcriptase (TERT), EGFR, 
and phosphatase and tensin homolog (PTEN) (Fig. 1, A and C, and 
table S1, A and C). In contrast, AC2 and AC3 subtypes enriched 
mutations of IDH1 and PDGFRA (Fig. 1, A and C, and table S1, 
A and C). Inspired by substantial interaction between the ARE and 
GIE subtypes, we sought to reconcile these two schemes and allo-
cated further more than 85% of GBM cases (cohort 1) into four 
ARE-GIE integrative (AGI) subgroups (table S1A), inclusive of 
AC1-MES (n = 19), AC1-CL (n = 10), AC2-PN (n = 5), and AC3-PN 
(n = 6). Univariate analysis affirmed the correlation of IDH muta-
tion with AC2-PN (P < 0.01, Fisher’s exact test) and EGFR alter-
ations with AC1-CL (P = 0.023, Fisher’s exact test). In line with the 
notion of massive remodeling of GBM microenvironment (28), gene 
signature–based portraying of tissue cellular landscape (by xCell) 
revealed subtype-associated immune/stromal cell composition, such 
as enrichment of monocytes, macrophages, and immature dendritic 
cells in AC1-MES, pericytes in AC1-CL, and regulatory T cells in 
AC3-PN (Fig. 1C, fig. S1H, and table S1C) (29). Notably, GIE-MES 
tumors generally had lower sample purity than GIE-CL and 
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Fig. 1. Landscape and clustering of active regulatory elements in GBM tissues. (A) Unsupervised hierarchical clustering of 1107 most-varying H3K27ac peaks (mean, ≥10; 
median absolute deviation, >1) across 49 GBM tissues (cohort 1) and 12 normal brain tissues. Top: The clinical, mutational, and molecular data of each sample. (B) Molecular 
classification of GBM samples in cohort 1 based on GIE subtypes and ARE subtypes. (C) Heatmap of differential enrichments of immune cell signatures, stromal cell signa-
tures, gene mutations, and clinical parameters among normal brain tissues and various molecular subtypes of GBM. (D) ARE clustering of an independent cohort of 46 GBM 
samples (cohort 2) based on the same set of 1107 variant elements that were identified from cohort 1. (E) Spearman correlation of ARE status in cohort 2 samples with 
each subtype centroids of cohort 1. (F) Summary of molecular GIE subtypes and ARE subtypes among cohort 2. AC, active regulatory element-based cluster; ARE, active 
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not influenced by variations in their purity. Hence, ARE sub-
type analysis and the AGI classification add a new layer of epig-
enomic information with interconnections to GBM clinical features, 
tumor microenvironment, genomic abnormalities, and transcrip-
tional subclasses.
To verify our ARE classification scheme in cohort 1, we included 
additional 46 cases of GBM tissues as an independent cohort 
(cohort 2; table S1D), of which 41 cases had cognate ChIP-seq and 
RNA-seq data (GIE-MES, n  =  13; GIE-CL, n  =  17; and GIE-PN, 
n = 11) (18). Similar observations were made in cohort 2 (Fig. 1, D to F, 
and table S1D), supporting a conservative pattern of three ARE sub-
types among GBM samples.
Rank ordering of clustered transcriptional enhancers 
in GBM subtypes
SE domains, characterized by excessive loading of H3K27ac on 
clustered enhancers, are shown to drive the expression of disease- 
promoting genes and cell identity regulators (30, 31). In total, we 
identified more than 85,000 SEs across 100 samples in the discovery 
cohort (table S1E; mean SE numbers: 848 in GBM tissues from co-
hort 1, 985 in normal brain tissues, 773 in GBM cells, and 966 in 
non-GBM cells). SE analysis substantially marked actively transcribed 
genes (fig. S2A). Inspired by seminal studies that small insertion variants 
in SE regions promote activation of oncogenes (32, 33), we sought 
to identify “recurrent enhancer-associated variants (RENVARs)” in 
primary GBM tissues based on variant discovery from H3K27ac reads 
inside both SE and typical enhancer (TE) regions (see Materials and 
Methods). We predicted 80 putative RENVARs (table S1F), of which 21 
were recorded as noncoding somatic mutation/indels in the Catalogue 
of Somatic Mutations in Cancer (COSMIC) database (e.g., single 
nucleotide variants at SE of PHLDA1; chr12:76030506) and 59 were 
not reported previously in either COSMIC or dbSNP (e.g., dinucleotide 
variants at SE of TGIF1; chr18:3449064). This list of RENVARs repre-
sents a valuable resource for further exploration of noncoding genomic 
variants in regulating gene expression during GBM development.
Next, we investigated topographies of SE domains that were 
associated with diverse molecular entities of GBM. To compare rela-
tive loading of H3K27ac among various GBM subtypes, we compiled 
all H3K27ac peaks from the same subtype and ranked stitched 
meta-enhancers by average ChIP-seq signals (Fig.  2A). Meta-SE 
signals showed a stronger correlation with the expression levels of 
target genes than promoter-transcription start site (TSS) signals, 
although both types of signals showed positive Spearman rank 
correlations (fig. S2B). Subtype- associated meta-SE genes showed a 
generally higher expression in that particular subtype when com-
pared with the rest of tumors (fig. S2C), while substantial overlaps of 
meta-SE domains among GBM subtypes compromised the pairwise 
comparison (fig. S2, C and D). In parallel, about half of nonrepetitive 
meta-SE–associated genes displayed subtype-specific engagement of 
SE domains, including those in proximity to signature genes of GIE 
subtypes such as TGFBI, SLC4A4, and EYA2 (fig. S2, D and E). To 
explore the connection between chromatin architecture and transcrip-
tional heterogeneity, we focused our analysis on AGI subtypes. At 
the level of meta- SE–associated genes, 13% were commonly present 
in all AGI subtypes despite variations in enhancer ranking (fig. S2D). 
AC1-MES and AC1-CL showed the highest degree of similarity 
(45%; Fig. 2B). In contrast, AC2-PN and AC3-PN differed consider-
ably at the SE landscape and SE-associated pathways (Fig. 2B and 
fig. S2, D and F), although both expressed a PN transcriptional sig-
nature. Subtype- specific meta-SE genes were overrepresented in 
Fig. 2. Subgroup-associated SE domains and disease pathways in GBM. (A) Relative rank of stitched H3K27ac ChIP-seq signals in integrative subtypes of GBM samples. 
Representative meta-SE–associated genes and their rankings in parentheses are highlighted. (B) Pairwise comparison of similarity in meta-SE–associated genes among inte-
grative subtypes of GBM samples. (C) Ontological enrichment of subtype-specific meta-SE–associated genes in GBM tissues. No significant pathways (Benjamini-Hochberg 








niversity of Sussex on Septem
ber 24, 2021
Xu et al., Sci. Adv. 2021; 7 : eabd4676     30 April 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 17
key pathways underlying disease biology, including stimulus response, 
leukocyte activation and cell migration in AC1-MES, and angio-
genesis in AC1-CL, as well as the neurogenesis pathway in AC3-PN 
(Fig. 2C). To complement the study of overall H3K27ac deposition, 
we interrogated frequency of individual SEs across each subtype. Our 
analysis identified 930 target genes that engaged subtype-enriched SE 
domains with statistical significance [odds ratio (OR), ≥2; P < 0.05, 
Fisher’s exact test; table S1G]. Intersection analysis further suggested 
activation of various phenotypic markers and druggable targets by 
subtype-enriched SEs (see details in table S1G). For instance, 
AC1-MES tumors showed biased enrichment of SE domains in two 
reported markers of MES GBM cells (34), namely, CD44 and CHI3L1, 
as well as several druggable targets such as LIMK2 and NAMPT 
(fig. S2G). Other potential actionable subtype-enriched SE targets 
included NUAK2 and WEE1  in AC1-CL, and FGFR2  in AC3-PN 
(fig. S2G and table S1G). Echoing the observations from meta-SE 
genes, ontological analysis of subtype-enriched SE targets in AC1-
MES samples reaffirmed their unique and robust association with 
stimulus response, cell migration, and immune response (fig. S2H), 
suggesting hyperactivation of these pathways via subtype-specific 
enhancer reprogramming. Subtype-enriched SE genes in AC3-PN 
were strongly enriched in neurogenesis and nervous system devel-
opment pathways (fig. S2H), suggesting that active and persistent 
engagement of neurogenic enhancers shapes AC3-PN identity. To-
gether, our integrative analysis delineates differential contribution 
of enhancer domains to GBM heterogeneity and subtype identity.
Asymmetrical engagement of tumor-specific SE domains 
in transcription regulators
To identify transcriptional enhancer domains that are associated 
with tumor specificity, we compared stitched H3K27ac signals be-
tween GBM (cohort 1) and normal brain tissues (Fig.  3A). Over 
those stitched enhancer regions showing hyperacetylation in GBM, 
preexisting H3K27ac signals were frequently detected in normal 
brain tissues. All of the 1806 GBM-associated meta-SEs were over-
lapped with either SE or TE domains in normal brain samples. At 
expression level, GBM- and normal-associated meta-SE genes showed 
biased expression in respective tumor and normal samples (fig. S3A). 
Genes driven by GBM-unique meta-SEs showed a greater degree of 
up-regulation in GBM than those associated with common meta-SEs 
(fig. S3B). These data suggest that GBM-associated SEs are devel-
oped from preexisting, developmental enhancers, prompting us to 
explore further enhancer remodeling during GBM development. 
More than 68% of meta-SE targets were exclusive to either GBM or 
normal brain tissues (Fig. 3B), suggesting a substantial reshaping of 
SE landscape during GBM development. In line with this, gene on-
tology (GO) and Reactome enrichment analysis of meta-SE–associated 
genes indicated sharp differences between GBM and normal brain 
samples. In GBM tissues, meta-SE–associated genes were strongly 
enriched in receptor tyrosine kinase signaling (e.g., EGFR) and reg-
ulatory region nucleic acid binding (e.g., RFX2 and TGIF1) path-
ways (Fig.  3,  C  and  D, and fig. S3C). In normal brain tissues, 
functions of meta-SE–associated genes were preferentially implicated 
in nervous system development (fig. S3C).
Meanwhile, in light of disease heterogeneity, we surveyed SE 
topography of individual samples from cohort 1 and detected 766 
GBM-associated SE domains (prevalence in GBM, >15%; OR, ≥2), 
of which 58% were absent in normal (table S1H). Top GBM- 
enriched SEs (n = 198; OR, ≥2; P < 0.05, Fisher’s exact test) were 
associated with many known Cancer Gene Census genes (table S1I) 
and prominent GBM drivers including EGFR and SOX2 (25, 35–37). 
Echoing the observations from the meta-SE approach, GO analysis 
of GBM-enriched SEs uncovered a robust enrichment of genes in-
volved in transcriptional regulation (Fig. 3E), indicative of exten-
sive rewiring of transcriptome. Next, to explore functional relevance 
of these transcriptional regulators, we performed a loss-of-function 
study of the top 10 GBM-enriched SE-driven TFs (OR, >10; P < 0.05, 
Fisher’s exact test), which showed concordantly overexpression in 
our discovery cohort (Fig. 3, F and G). Depletion of each TF atten-
uated the viability of both established GBM cells and GPCs (Fig. 3F 
and fig. S3, D and E). Expression of the majority of the abovemen-
tioned TFs (e.g., BCL6, ETS1, SOX2, JUN, PRRX1, and TGIF1) was 
consistently elevated in GBM samples relative to nontumor brain 
across three independent datasets (i.e., Gravendeel, Rembrandt, 
and TCGA-GBM) (6, 38, 39), implicative of a strong clinical rele-
vance of SE-driven TFs (fig. S3, F to H). Orthotopic xenograft 
experiments using NNI-11 patient-derived GPCs demonstrated 
further unrecognized roles of RFX2 and TGIF1, two of the exam-
ined SE-driven TFs with high OR in tumor, in promoting GBM 
tumorigenicity (Fig.  3,  H  and  I). Silencing of either RFX2 or 
TGIF1 in GPCs conferred a marked survival benefit on recipient 
immunocompromised animals. The deleterious impact of RFX2 
and TGIF1 knockdown on tumor growth was independently veri-
fied in a subcutaneous xenograft model using U251 GBM cells (fig. 
S3I). In addition, transcriptional level of either RFX2 or TGIF1 was 
associated adversely with the prognosis of patients with glioma 
(Fig. 3J). To extend these findings, we generated an SE-regulated TF 
signature based on their frequency and enrichment in either GBM 
or normal tissues (Fisher’s exact test; see detailed criteria in table 
S1J). This signature consisted of top TFs with differential SE en-
gagement (GBM enriched, n = 10; normal brain enriched, n = 12) 
and demonstrated its capability to stratify various clinical elements 
including age, pathology, and survival (Fig. 3K and table S1, J to L). 
Together, these observations suggest that GBM engages specific SE 
domains in productive expression of oncogenic TFs to foster malig-
nant progression.
SE-driven core TFs and regulatory circuitries in GBM
Along with preferential engagement of GBM-specific SE domains 
in tumor-promoting TF genes (Fig. 3E), motifs of many SE-driven 
TFs (e.g., SOX2, JUN, and RFX2) were highly enriched in SE re-
gions (fig. S4A). Consistently, SE-driven TFs in each GBM subtype 
had extensive binding sites across the meta-SE regions of respective 
subtypes (fig. S4B). To elucidate transcriptional homeostasis under-
lying subtype identity, we reversely engineered core TF network 
based on SE engagement and regulatory connectivity, using a model 
of core transcriptional regulatory circuitry (40–42). Our computa-
tional analysis uncovered groups of SE-driven master TFs, which 
collaborated on interconnected regulatory circuitries in each sub-
type (Fig. 4A and fig. S4, B to D). Notably, SOX2, NR2F1, IRF9, 
FOXO3, ETV6, and RARA were shared as common master TFs 
among all GBM subtypes and normal brain tissues, implicating 
their general association with lineage/tissue specificity. ETS1, RFX2, 
PRRX1, FOXK1, IRF1, NR2F2, and MEIS2 served as tumor-specific 
core TFs in at least three subtypes. PKNOX2, BCL6, MAZ, and 
POU3F2 occurred preferentially in circuitries among PN samples. 
Notably, targeting bromodomain and extraterminal domain (BET) 
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Fig. 3. GBM-promoting transcription factors preferentially engage tumor-enriched super-enhancers. (A) Relative rank of stitched H3K27ac ChIP-seq signals in GBM 
(cohort 1) and normal brain tissues. Representative meta-SE–associated genes and their rankings in parentheses are highlighted. (B) Venn diagram showing common and 
sample type–specific meta-SE–associated genes in GBM and normal brain tissues. (C and D) Differential deposition of H3K27ac signals across regulatory regions of EGFR, 
RFX2, and TGIF1. (E) Ontological analysis of GBM-enriched SE genes. (F) Association of GBM-enriched SE domains with TFs and effect of shRNA-mediated silencing of top 
SE-associated TFs on cell viability of U251 GBM cells and NNI-11 GBM-propagating cells. (G) Elevated expression of TFs driven by tumor-enriched SEs in GBM samples 
(cohort 1). Student’s t test (two tailed) was applied. Boxplots represent the 25th and 75th percentiles, with midlines indicating the median values and whiskers extended 
to the lowest/highest values. (H and I) Effect of shRNA-mediated silencing of either RFX2 (n = 8) or TGIF1 (n = 7) in NNI-11 cells on survival of recipient mice with intracra-
nial xenografts. Before intracranial implantation, Western blot and qPCR analyses were used to verify effective silencing of RFX2 and TGIF1, respectively. (J) Prognostic 
potentials of RFX2 and TGIF1 in Rembrandt cohort of glioma patients. (K) Prognostic potentials of an SE-driven TF signature in three independent cohorts of glioma pa-
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proteins] effectively disrupted the expression of AC1-MES core 
TFs (e.g., TEAD1, SOX9, MYC, and NFIL3) in an MES subtype 
model U87 cells (Fig. 4B) (43), suggesting a critical role of BET 
proteins in maintaining GBM transcriptional regulatory circuitries. 
Coexpression analysis further revealed that at least two cliques of 
closely correlated TFs in each subtype: a “stemness” module contain-
ing SOX2, NR2F1, and recurrent cooperating TFs that are involved 
in neuronal stem cell maintenance, and a “proliferation” module 
Fig. 4. Subgroup-associated core regulatory circuitries in GBM. (A) Core interconnected transcriptional regulatory circuitries in each integrative subtype of GBM 
tissues. Core TFs are highlighted in colored circles. Key interactive partners of core TFs are indicated in gray circles. (B) Heatmap showing response of AC1-MES core TFs 
to a BET protein degrader (dBET6, 500 nM) treatment in U87 cells (GSE99181; transcripts per million, > 0.1). (C) Enhanced deposition of H3K27ac signals across regulatory 
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containing ETS family, AP-1 factors, and additional members with 
known functions in cell cycle and angiogenesis (Fig. 4, C and D, 
and fig. S5). These modular TFs co-operated with diverse core TFs 
to establish and maintain the GBM molecular subgroup identity. 
Together, our computational reconstruction depicts a blueprint 
of core TFs and their interconnected regulatory circuitry for each 
integrative molecular subtype.
Catalog of SE-associated long noncoding RNAs in GBM
Widespread transcription from the non–protein coding genome 
prompted us to explore potential involvement of SEs in the 
regulation of long noncoding RNAs (lncRNAs). At least 15% of 
GBM- associated SE domains were mapped primarily to annotated 
lncRNAs including antisense RNAs (fig. S6A). After filtering out 
those with either undetectable or low [mean fragments per kilobase 
Fig. 5. SE-driven lncRNAs in GBM. (A) Elevated expression of SE-driven lncRNAs in GBM samples (cohort 1). Student’s t test was applied. (B) Differential deposition of 
H3K27ac signals across regulatory regions of LINC01094 and MIR99AHG in GBM subtypes and normal brain tissues. (C to E) Effect of shRNA-mediated silencing of 
LINC01094 and MIR99AHG on target expression (C) and cell viability (D), and survival of recipient mice with intracranial transplantation of NNI-11 cells (E). (F) Differential 
expression of LINC01094 and MIR99AHG transcripts among various human cancers. (G) Effect of BET protein degraders on the expression of LINC01094. U87 and U251 
GBM cells were treated with either ZBC260 or dBET6 (200 nM, 8 hours) before harvest. (H) Effect of siRNA-mediated silencing of core TFs on the expression of LINC01094. 
GBM cells were transfected with indicated siRNAs (48 hours) and subjected to qPCR analysis. Either one-way ANOVA or t test was used for analysis of significance. Error 
bars in (C), (D), (G), and (H) represent SEM, n = 3. Log-rank test was applied for survival analysis in (E). Boxplots in (A) and (F) represent the 25th and 75th percentiles, with 
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Fig. 6. Analysis of GBM-enriched SEs uncovers actionable drug targets. (A) Engagement of GBM-enriched SE domains in druggable genome. (B) Chemical structure 
and biochemical activity of an MNK kinase inhibitor ETC-168. (C) Effect of ETC-168 on viability of GBM cells and GBM-propagating cells. (D and E) Effect of ETC-168 treatment 
on sphere formation capability (SFC) of GBM-propagating cells (i.e., NNI-11). (F) Effect of ETC-168 (5 M) and TMZ (100 M) on expression of downstream targets in NNI-11 
cells after 24-hour treatment. (G) Effect of ETC-168 (5 M) and temozolomide (TMZ; 100 M) on viability of NNI-11 cells after 72-hour treatment. One-way ANOVA was used 
for analysis of significance. (H) Effect of ETC-168 [25 mg/kg, orally (po), twice a day (bid)] and TMZ (100 mg/kg, po, once a day (qd)] on expression of indicated proteins in 
orthotopic xenograft tumors (NNI-11) after 24-hour treatment. (I) Effect of ETC-168 and TMZ treatment on both survival of recipient mice with intracranial transplantation 
of NNI-11 cells and the tumor incidence at the end point of experiment. Log-rank test was applied for survival analysis; n = 6 or 7. (J and K) Effect of shRNA-mediated 
silencing of either MKNK1 or MKNK2 in NNI-11 cells on survival of recipient mice (J) and orthotopic tumor expansion 2 months after implantation (K). Log-rank test was 
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of transcript per million mapped reads (FPKM), <0.5] expression in 
our discovery cohort, we identified a list of nine SE-associated 
lncRNAs whose expression was up-regulated selectively in GBM 
tissues (for SE: OR > 2, Fisher’s exact test; for expression: P < 0.05, 
Student's t test) (Fig. 5A). Among these, LINC01094 and MIR99AHG 
(LINC00478) demonstrated elevated H3K27ac deposition in their 
regulatory regions in GBM samples except for the AC3-PN sub-
type (Fig. 5B). Genetic depletion of LINC01094 and MIR99AHG, 
both of which showed glioma-specific expression compared with other 
human malignancies, impaired GBM cell viability and tumorige-
nicity (Fig. 5, C to F, and fig. S6B). Defective expression of either 
LINC01094 or MIR99AHG in GBM cells compromised tumor growth 
in subcutaneous xenograft models (fig. S6B) and conferred a survival 
benefit to recipient animals in independent orthotopic xenograft 
models (Fig. 5E). Next, with a focus on LINC01094, we showed further 
that both BET proteins and disease- relevant core TFs (including 
MYC, ETV6, and NR2F2) contributed to the productive expression 
of this lncRNA in GBM cells (Fig. 5, G and H). Hence, LINC01094 
represents an example of oncogenic lncRNA whose disease-specific 
expression is regulated through tumor-associated core TFs and SE 
domain. Together, these data functionally annotates LINC01094 and 
MIR99AHG as GBM- promoting lncRNAs with disease specificity. 
SE-associated lncRNAs represent an additional source of disease 
dependencies and biomarkers.
Engagement of GBM-associated SE domains 
in druggable genome
In line with the notion that GBM-specific and GBM-promoting 
genes are frequently associated with SE domains, we hypothesize 
that analysis of SE-associated druggable genes favors discovery of 
actionable cancer dependencies. To identify potential therapeutic 
targets whose expressions are regulated by GBM-associated SEs, we 
interrogated the common hits between SE-associated protein-coding 
genes and the druggable genome based on DGIdb (Drug Gene 
Interaction Database). More than 160 candidates were retrieved 
from this analysis, including the aforementioned EGFR and many 
others with actionable small molecules, e.g., BRD4, CDK13, WEE1 
and MKNK2/MNK2 (Fig. 6A and table S1M). Immunoblot assay 
also verified the prevalent up-regulation of BRD4, CDK13, WEE1, 
and MNK2 proteins in GBM tissue lysates (fig. S6C). Given the pro-
found function of BET bromodomain proteins in maintaining SE 
output and gliomagenesis (43), engagement of tumor- specific SE 
domains to BRD4 suggests a feed-forward mechanism of transcrip-
tional dysregulation in a subset of GBM cases. A potent BET protein 
degrader, ZBC260 (44), exerted a picomolar to low nanomolar anti-
proliferative efficacy against both GPCs and established GBM cell 
lines (fig. S6D). In addition, we demonstrated the preclinical anti- 
GBM activities of THZ531 (CDK12/13 inhibitor), Adavosertib/
AZD1775 (WEE1 inhibitor), and CGP57380 (MNK1/2 inhibitor) 
(fig. S6D). To strengthen translational potential of our findings, 
we tested a recently developed MNK inhibitor (ETC-168) with de-
sirable potency and brain penetrance (Fig. 6, B to I) (45). ETC-168 
treatment blocked both GBM cell proliferation and GPC self-renewal 
(Fig. 6, C to E). ETC-168 treatment induced cleavage of both caspase-3 
and poly(ADP-ribose) polymerase 1 (PARP1) in GPCs, which was ac-
companied by a sharp down-regulation of p-EIF4E (Fig. 6F). 
Moreover, ETC-168 displayed an additive effect with TMZ to in-
hibit cell viability (Fig. 6, F and G). Similarly, ETC-168 treatment 
was able to reduce p-EIF4E in orthotopic xenografts and cooperated 
with TMZ to elicit cleavage of PARP1 in  vivo (Fig.  6H). Despite 
limited survival benefit from ETC-168 as a single-agent regimen 
in vivo, combination of MNK inhibitor and TMZ not only pro-
longed the overall survival of tumor-bearing mice but also resulted 
in a cure of disease as evidenced by the tumor-free animals at the 
experimental end point (Fig. 6I). Promising anti-GBM activity of 
the drug combo of MNK inhibitor and TMZ encourages further 
clinical translation and repositioning of relevant compounds in 
trials (46, 47). In addition, genetic depletion of either MKNK1 
(MNK1) or MKNK2 (MNK2) attenuated concordantly both GBM 
cell expansion and tumorigenicity, with MNK2 knockdown confer-
ring a greater survival benefit on recipient mice (Fig. 6, J and K, and 
fig. S6, E and F). Together, these data suggest valid engagement of 
tumor-associated SE domains in druggable GBM addictions.
DISCUSSION
In this study, we have analyzed the landscape of transcriptionally 
active chromatin across a series of 95 fresh-frozen GBM specimens, 
12 normal brain samples, and 38 cell lines. Integrative analysis of 
differentially regulated AREs, especially SE domains, informs on 
previously unrecognized oncogenic dependencies, molecular clas-
sification, and epigenetic regulation of subtype identity. Our data 
also serve as a valuable resource to the research community to ex-
plore epigenetic mechanisms underlying GBM and normal brain 
activities.
Through profiling of transcriptionally active chromatin, our 
study narrows the gap between epigenetic dysregulation and tran-
scriptional diversity. Our unbiased analysis of AREs and gene ex-
pression in primary tissues supports a generally positive correlation 
between overall enhancer signals and expression of target genes. 
However, differences in clustering were observed between ARE 
classification and expressional classification, although both mea-
sured active gene expression. Our data reveal an additional layer 
of GBM heterogeneity at the level of AREs, complementing the 
current molecular classification, which is largely dependent on gene 
expressional signatures. Our integrative analysis classified GBM into 
four integrative molecular subtypes, namely, AC1-MES, AC1-CL, 
AC2-PN, and AC3-PN. Unexpectedly, AC1-MES and AC1-CL tumors 
had a similar ARE architecture including SE topography (Fig. 1, 
A and B), despite showing distinct gene expression clustering and 
tumor purity. Hence, H3K27ac-based clustering analysis of MES and 
CL tumors was unlikely confounded by their tumor purity. However, 
coclustering of samples upon unsupervised hierarchical clustering 
of AREs does not equal to being “epigenetically identical” between 
AC1-MES and AC1-CL. GO analysis of subtype-biased SE targets 
indicated a marked difference in pathway enrichment between 
AC1-MES and AC1-CL. Divergence of transcription between AC1-
MES and AC1-CL is likely contributed by subtype-specific enhancers 
(Fig. 2C and fig. S2H), as well as additional mechanisms involving 
tumor microenvironment, cellular heterogeneity (11, 48), and post-
transcriptional regulation of mRNA (49). In support of this notion, 
AC1-MES tumors showed the highest immune scores and selective 
enrichment of SE genes in immune response pathways, while 
AC1-CL tumors harbored gene signatures of pericytes and angio-
genesis pathway. Single-cell transcriptome analyses further support 
strong immune cell infiltration and inflammatory reactions within 
MES tumors (48). AC2-PN and AC3-PN differed substantially in 
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signature. The identification of “epigenetically divergent” PN samples 
implicates distinct pathobiology, which is masked by their similarity 
in transcriptional signatures. ARE topography of AC3-PN resem-
bled generally that of normal brain (Fig. 1A). AC3 GBM and normal 
brain samples were also coclustered with one grade 3 oligoastrocytoma 
(fig. S1D and table S1A), suggesting a tendency toward lower malig-
nancy and a better prognosis. SE-associated genes in AC3-PN were 
skewed toward stimulus response, cell projection, and cell motility 
pathways when compared with those in AC2-PN. Strong enrich-
ment of neurogenesis pathways in AC3-PN tumors suggests inher-
itance of a neurogenic, active chromatin state during transformation. 
Hence, malignant traits of AC3-PN tumors are established by inte-
gration of PN enhancers and associated core TFs (e.g., NFIA, EGR1, 
CDX1, PKNOX2 and NKX2-2). Preferential enrichment of IDH 
mutations in AC2-PN may underpin its unique ARE features. Nev-
ertheless, the existence of IDH–wild-type AC2-PN samples impli-
cates that the H3K27ac landscape of AC2-PN can be established by 
mechanisms independent of IDH mutation. As IDH-mutant gliomas 
have been recognized by their distinct DNA methylation profiles, 
chromatin state, and aberrant chromosomal topology compared 
with IDH–wild-type counterparts (7, 50–52), IDH mutation in-
duces both DNA hypermethylation and chromatin dysfunction 
and likely co-operates with dysregulated histone acetylation to shape 
AC2-PN subtype identity. These data, in turn, predict that combi-
natory targeting of IDH and histone acetylation axis (e.g., agents 
against HDAC and BET bromodomain proteins) is a promising 
strategy to impair epigenetic dependency of IDH-mutant gliomas.
Our ARE profiling of primary tumor biopsies provides clinically 
relevant chromatin information. Integrated classification of GBM 
revealed strong correlation of ARE status with various pathological 
and genomic features, implicating its strong clinical relevance. 
Study of differentially engaged SEs uncovered both tumor-specific 
and subtype-specific regulation of target genes, including TFs (e.g., 
RFX2 and TGIF1), lncRNAs (e.g., LINC01094 and MIR99AHG), 
and druggable targets (e.g., MKNK2, BRD4, and WEE1). Although 
the precise cell of origin of each GBM tumor remains unknown, 
various animal genetic studies have revealed oncogenic transforma-
tion of neural stem cells, early progenitors, astrocytes, and neurons 
into malignant glioma (53). Because neurons and glial cells make up 
the majority of cells in the adult brain, normal brain tissues from 
anatomical regions with a relatively higher incidence rate of GBM 
can serve as surrogate controls for GBM samples. TFs are overrepre-
sented among GBM-specific SE targets, highlighting the extensive 
remodeling of transcriptional network. In line with this, TF-centric 
SE signature genes that were extracted from GBM can faithfully 
stratify patient survival, tumor grade, and other molecular features of 
gliomas in patient cohorts. Reverse-engineering of core transcriptional 
circuitry outlined at least two conserved core modules of master TFs 
governing either stemness or proliferation across all GBM. Hence, 
two cliques of master TFs collaborate on propagation of GBM cells. 
Additional cooperating SE-driven TFs then extend the core regula-
tory network and skew transcriptional output toward a particular 
cell state and disease subtype. Moreover, the conservation and 
modular composition of stemness and proliferation TFs among GBM 
samples coincide with the phenotypical dichotomy of GPCs (13). 
GBM cellular states ranging from PN to MES and from noncycling 
to cycling may reflect the gradient activities of two modular TFs. 
Our study suggests that therapeutic agents targeting BET bromo-
domain proteins are promising modalities to break core regulatory 
circuitries. We further report a strong anti-GBM activity of a BET 
protein degrader ZBC260.
In an effort to target additional SE-associated druggable targets, 
we tested an MNK inhibitor ETC-168 against GBM cells. Our data 
support the brain penetrance of ETC-168 based on the observation 
that ETC-168 reduced p-EIF4E in orthotopic tumors. However, we 
observed a stronger in  vitro anti-GBM activity of ETC-168 than 
in vivo. This discrepancy is likely caused by reduced bioavailability 
of ETC-168 in the animal brain, as it exerted a relatively weaker 
inhibitory effect on p-EIF4E in GBM cells in vivo, when compared 
with in vitro treatment. Albeit future efforts are required to develop 
optimal delivery strategy by improving dosing and schedule of 
single-agent treatment, our data indicate a promising brain pene-
trance of ETC-168 and in vivo activity of ETC-168/TMZ combo in 
tumor-bearing mice. Notably, MNK silencing exerted a greater im-
pact on GBM tumor growth than MNK inhibition by ETC-168. In 
addition to bioavailability, kinase-independent role of MNK pro-
teins may account for such a difference. Strong deleterious effects of 
MNK silencing on cancer cells encourage further development of 
MNK-degrading agents.
We also uncover many SE-driven functional targets/pathways 
that are associated with subtype specificity, encouraging follow-up 
studies to explore actionable tumor dependencies. Considering the 
possibility that multiple genes can be regulated through a single 
broad SE domain, the number of SE-associated targets is very likely 
underestimated, especially for lncRNAs. Our ARE dataset serves as 
a fertile ground for future hypothesis testing and in-depth biologic 
exploration (especially for lncRNAs). On the basis of our data, more 
sophisticated scoring systems may be developed to fulfill optimal 
mapping of both subtype-specific engagement of SE domains and their 
targets. With recent insights from the function of extrachromosomal 
circular DNAs in driving oncogene expression, genomic abnormal-
ities, especially amplification and/or reintegration of noncoding 
regulatory DNA elements, greatly enhance oncogenic transcription 
(54–56). We anticipate that integration of extra layers of genomic and 
epigenetic information, including DNA abnormalities/modification 
(57–59), chromatin accessibility (60), and chromatin conformation 




All cell lines tested negative for mycoplasma and have been authen-
ticated by short tandem repeat analysis with the Geneprint 10 System 
Kit (Promega). Human embryonic kidney 293T [American Type 
Culture Collection (ATCC)], U87-MG (U87, ATCC), U251-MG 
(U251, Sigma-Aldrich), and U343-MG (U343, ATCC) cell lines were 
cultured in Dulbecco's modified Eagle medium (DMEM; Biowest). 
DBTRG-05MG (DBTRG, ATCC) cells were maintained in Roswell 
Park Memorial Institute medium 1640 (Biowest). For the aforemen-
tioned cells, culture media were supplemented with 1% penicillin- 
streptomycin (Gibco) and 10% fetal bovine serum (Biowest).
Patient-derived GPCs including NNI-11, NNI-20, NNI-23, NNI-24, 
and NNI-31 were provided by the National Neuroscience Institute 
(NNI), Singapore. These GPC cell lines were established from patient 
tumors obtained with informed consent and deidentified in accor-
dance with the SingHealth Centralised Institutional Review Board 
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Board A. MGG4 and MGG8 were provided by H.W. All GPCs were 
expanded as tumor spheres that were maintained in growth media 
consisting of epidermal growth factor (20 ng/ml), basic fibroblast 
growth factor (20 ng/ml), heparin (5 g/ml), B27 supplement (Gibco), 
and DMEM/F-12 mixture (3:1). All cell cultures were maintained in 
5% CO2 in a humidified incubator at 37°C. Information of cell lines 
we used for H3K27ac ChIP-seq analysis can be found in table S1B.
Chemicals and plasmids
ZBC260 was provided by S.W., University of Michigan. dBET6 was 
provided by J. Bradner, Harvard Medical School. ETC-168 was 
shared from the Experimental Drug Development Centre, Agency 
for Science, Technology and Research, Singapore. Other key chemi-
cals used in this study included THZ531 (ApexBio), CGP57380 
(Abcam), Adavosertib (Medchem Express), TMZ (ApexBio), and 
formaldehyde (Calbiochem, Merck).
On-TARGETplus small interfering RNA (siRNA) pools includ-
ing control (si-NT), si-ETV6, si-MYC, and si-NR2F2 were purchased 
from Dharmacon. RNAiMAX (Life Technologies) was used to 
transfect siRNAs. Stable knockdown cells were generated by lentiviral 
infection, followed by antibiotic (puromycin, Sigma-Aldrich) selection. 
SHC002 was used as a negative control (sh-Ctrl). All pLKO.1-based 
short hairpin RNA (shRNA) vectors are listed in table S1N. 293T cells 
were used for viral production.
Cell viability assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay was performed to measure the cell viability of U87 and U251 
cells (62). Briefly, GBM cells were seeded into 96-well plates at 2000 
cells per well and cultured under indicated treatment. MTT substrate 
was added into each well and incubated for 3 hours, followed by 
careful aspiration of medium and addition of 100 l of MTT Stop 
solution. Plates were read on a Tecan microplate reader with the 
absorbance at 570 nm.
CellTiter-Glo assay (Promega) was applied to measure the cell 
viability of GPCs. Tumor spheres were dissociated by Accutase 
(Gibco) and subsequently seeded into a 96-well plate at either 2000 
or 3000 cells per well. Following indicated drug treatment, lumines-
cence signals were measured after 72-hour incubation. For cells 
with shRNA transduction, luminescence signals were detected at 
both days 1 and 5 after seeding.
In vitro limiting-dilution tumor sphere formation assay
GPCs were dissociated by Accutase, seeded into low-attachment 
96-well plates (Corning) with decreasing numbers of cells per well, 
and cultured with indicated treatment. Tumor sphere forming 
capability was examined by Extreme Limiting Dilution Analysis 
(http://bioinf.wehi.edu.au/software/elda/).
Animal models
Both subcutaneous and intracranial xenograft models were used to 
evaluate the tumorigenicity of GBM cells either after genetic ma-
nipulation or in response to drug treatment, in compliance with 
ethical regulations of the National University of Singapore (NUS) 
Institutional Animal Care and Use Committee. Regarding the sub-
cutaneous xenograft assays, half a million of indicated GBM cells 
were resuspended with 100  l of Matrigel (Corning)/phosphate- 
buffered saline (PBS) solution (volume ratio, 1:1) and injected sub-
cutaneously on the upper flanks of NOD/SCID gamma (NSG) mice 
(male, 6 to 8 weeks old). Tumors were dissected from animals and 
weighed at the experimental end point.
For orthotopic xenograft models, 6- to 8-week-old male NSG 
mice were used for stereotaxic cell implantation (0.2 million cells in 
2 l of PBS). In preparation for histological examination, mouse 
brains were harvested by transcardial perfusion with 4% para-
formaldehyde when mice either reached experimental end points 
or fulfilled humane end point criterion (20% loss of peak body 
weight or presented with neurological defects, such as ataxia, ca-
chexia, lethargy, or seizure). Animal survival was recorded on the 
basis of humane end point criterion.
For in vivo drug treatment, mice bearing intracranial tumors 
were randomly allocated into each treatment arm 1 week after 
implantation. Mice in the experimental arm received oral gavage of 
indicated compounds. TMZ was given at a dose of 100 mg/kg, once 
a day, 5 days per week for 2 weeks; ETC-168 was given at a dose of 
25 mg/kg, once a day, 5 days per week for 5 weeks. Animals in the 
control arm received the same volume of vehicle (100 l of Ora-Plus 
Oral Suspending Vehicle, Paddock Laboratories). For immunoblot 
analysis, fresh tumor tissues were harvested from these experimental 
animals.
No specific randomization methods were used to allocate mice 
into different treatment groups. The investigators were not blinded 
to allocation during either experiments or outcome assessment. 
Minimum sample sizes for individual experiments were determined 
on the basis of our experience (n ≥ 5). No animals were excluded 
from these experiments.
Cell/tissue lysate preparation and immunoblot assay
Whole-cell lysate was extracted by incubating cells in lysis buffer 
[50 mM tris (pH 8.0), 420 mM NaCl, 5% glycerol, 0.1% NP-40, and 
0.1 mM EDTA] with fresh addition of 1 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, 1× protease inhibitor cocktail (Roche), 
1× phosphatase inhibitor cocktail (Roche), 1 mM MgCl2, and Benzonase 
(1:500, Novagen) for 20 min on ice. To extract proteins from tis-
sues, the same lysis buffer was added to minced samples and subse-
quently passed through a 1-ml syringe with a 26-gauge needle for 
several times. Clear supernatant after centrifugation (13,000 rpm, 
10 min) was carefully transferred to a new tube and subjected to 
protein concentration quantification by Bradford assay (Bio-Rad). 
Immunoblot analysis was conducted following standard protocol 
with the following antibodies: -actin (Sigma-Aldrich, A1978), 
BCL6 (Sigma-Aldrich, HPA004899), BRD4 (Cell Signaling Tech-
nology,13440S), CDK13 (Genetex, GTX102408), cleaved caspase-3 
(Cell Signaling Technology, 9661), cleaved caspase-7 (Cell Signal-
ing Technology, 8438S), cleaved PARP (Cell Signaling Technology, 
9661), EIF4E (Cell Signaling Technology, 2067), ETS1 (Cell Signaling 
Technology, 14069), JUN (Cell Signaling Technology, 9165S), MNK1 
(Cell Signaling Technology, 2195), MNK2 (Sigma-Aldrich, HPA021875), 
p-EIF4E (Abcam, ab76256), RFX2 (Sigma-Aldrich, HPA048969), 
SOX2 (Cell Signaling Technology, 3579S), and WEE1 (Cell Signaling 
Technology, 13084S).
Chromatin immunoprecipitation
Pathologically reviewed either human GBM or normal brain sam-
ples were collected from the National University Hospital Tissue 
Repository, the First Affiliated Hospital of Soochow University, and 
the Cedars-Sinai Medical Center, with study approvals from their 
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ChIP procedures in this study were in line with a previously 
published protocol (63). Briefly, either Douncer-homogenized tis-
sue samples or dissociated cells were fixed with 1% formaldehyde 
(10 min, room temperature), washed three times with cold PBS, and 
subjected to nuclei isolation. Enriched nuclei were then resuspended 
in lysis buffer [1% SDS, 10 mM EDTA, and 50 mM tris (pH 8.0)] for 
10 min on ice and sonicated by Bioruptor (Diagenode). After soni-
cation, chromatin DNA was sheared into 200 to 500 base pairs (bp), 
and cell debris was removed by centrifugation. Supernatant was 
then incubated with Dynabeads (Invitrogen), which were precon-
jugated with antibodies specific to H3K27ac (Active Motif, 39133). 
After overnight incubation in the cold room, magnetic beads were 
subjected to a stepwise wash process with low-salt wash buffer, 
high-salt wash buffer, LiCl wash buffer, and TE buffer. ChIP-ed 
DNA was reverse-crosslinked (65°) and purified by MinElute PCR 
(polymerase chain reaction) Purification Kit (Qiagen). Eluted 
DNA was quantified by Qubit dsDNA HS Assay (Thermo Fisher 
Scientific).
Genomic DNA extraction and Sanger sequencing
A small aliquot of either GBM tissue or GPC pellet was reserved for the 
extraction of genomic DNA (Qiagen DNeasy Blood and Tissue Kit). 
Genomic DNA from the normal brain was included as negative control. 
Target region spanning C228T and C250T mutations in the TERT pro-
moter (64), corresponding to c.−124C>T and c.−146C>T of TERT ATG 
start site, was PCR amplified by GoTaq Green Master Mix (Promega) 
with the following primer set: 5′-GTCCTGCCCCTTCACCTT-3′ 
(forward) and 5′-AGCACCTCGCGGTAGTGG-3′ (reverse). IDH1 
genomic DNA harboring the region corresponding to hotspot 
mutation R132 was amplified using the following primer set (65): 
5′-AATGAGCTCTATATGCCATCACTG-3′ (forward) and 
5′- TTCATACCTTGCTTAATGGGTGT-3′ (reverse). Amplicons 
were Sanger sequenced to identify the mutational status.
RNA preparation and quantitative reverse transcription PCR
Total RNA was extracted by RNeasy Kit (Qiagen) and treated with 
deoxyribonuclease. RevertAid RT Reverse Transcription Kit (Thermo 
Fisher Scientific) was used to produce complementary DNA library 
for quantitative reverse transcription PCR (qRT-PCR) assay. qPCR 
was performed with Kapa SYBR Fast qPCR Master Mix (KAPA 
Biosystems) on a 7500 Real-Time PCR System (Applied Biosyste-
ms). qRT-PCR primers are listed in table S1O (66).
ChIP-seq analysis
For our in-house samples, ChIP-seq libraries were constructed using 
a ThruPLEX DNA-seq Kit (Rubicon Genomics). Next-generation 
sequencing was performed by BGI Tech Solutions Co. Ltd. and 
NovogeneAIT Genomics Singapore Pte Ltd. Raw ChIP-seq files for 
published data with controlled access (table S1A) were downloaded 
via Sequence Read Archive (SRA) tools from the database of Genotypes 
and Phenotypes (dbGAP), with approvals from their respective Data 
Access Committees (DACs). Other publicly available ChIP-seq data 
were uniformly processed, and the quality control information can 
be found in table S1 (A, B, and D).
For ChIP-seq data analysis, some of the following methods are 
similar to those previously published (63). Raw reads were aligned 
to hg38 reference genome using bwa v0.7.13-r1126 aligner followed 
by removal of PCR duplicates with Picard v2.5.0 markDuplicates 
utility (67). Resulting bam files were used for peak calling with 
MACS2 v2.1.4 by extending reads to fragment size predicted by 
strand cross-correlation analysis from phantompeakqualtools v1.0 
and parameter --nomodel (68, 69). ChIP signals (bedGraph) were 
simultaneously generated, and input signal was subtracted with 
MACS2 bdgcmp function. bedGraphs were later converted to big-
wig files with the UCSC bedGraphTobigWig utility. Detected peaks 
were annotated with HOMER v4.10 annotatePeaks. The ROSE 
(Rank Ordering of Super-Enhancers) algorithm (https://bitbucket.
org/young_computation/rose) was applied to identify SEs. Regions 
within ±1250 bp from TSS were excluded for this analysis. For each 
sample, input-subtracted ChIP-seq signals were stitched and ranked 
on the basis of intensity. A geometrical inflection point was 
used as cutoff to separate SEs from TEs. SE association was an-
notated to Ensembl genes with default setting. Regarding meta- 
SE analysis, H3K27ac signals of all samples within each subgroup 
were merged as single input and subjected to SE calling. Core 
transcriptional regulatory circuitries were computationally re-
constituted by CRCmapper (40, 41) based on the frequency of 
TF motifs within SE domains. Top-ranked circuitry and key- 
predicted interactive factors were visualized in Cytoscape with 
GeneMANIA (70). Motif enrichment analysis of SE-driven TFs 
was performed using MEME software (71). GO analysis of SE 
target genes was calculated by g:Profiler (72) with significance 
threshold set to Benjamini-Hochberg false discovery rate (FDR) 
(0.05) and subsequently visualized in Cytoscape with Enrich-
ment Map (73).
RENVARs were identified by adapting a variant calling work-
flow from DNA-seq. The ChIP-seq bam files were processed on the 
basis of the Genome Analysis ToolKit (GATK) best practice. Brief-
ly, the bam files were subjected to base recalibration, and variants 
were called using the GATK v4.0.1 Mutect2 (74) on the recalibrated 
bam files. Only variants that passed all default filters of GATK 
FilterMutectCalls were retained for downstream analyses. The 
variants were annotated using ANNOVAR v2019-10-24 (75), and 
variants that were present in normal tissues, exonic, annotated as 
benign/likely benign, having (ExAC and gnomAD) population allele 
frequency ≥0.01, depth <50, or alternate allele depth <5 were re-
moved. COSMIC89 and dbSNP150 (avsnp150) were interrogated 
to filter out reported variants unless listed as somatic noncoding 
mutations. The remaining variants were then intersected with the 
MACS2 called H3K27ac peaks using bedtools v2.29.2 to identify 
enhancer- associated hits. Table S1F shows the list of RENVARs 
(occurred in two or more samples).
RNA-seq and gene expression analysis
RNA-seq libraries were constructed by the TruSeq Library Prep Kit 
(Illumina) and sequenced at BGI Tech Solutions Co. Ltd. (HiSeq, 
paired-end reads of 100 bases). Paired-end reads were aligned to hg38 
genome using STAR v2.5.3a and subjected to transcript quantification 
using RSEM v1.3 based on Gencode v24 annotation (76, 77).
Variant identification was performed using STAR v2.5.3a and GATK 
v3.8 based on the best practice guideline outlined (https://gatk.
broadinstitute.org/hc/en-us/articles/360035531192- RNAseq- 
short-variant-discovery-SNPs-Indels-) (74, 78). Briefly, the RNA-
seq data were mapped to human genome hg38 using STAR 2.5.3a 
two-pass workflow. Subsequently, upon marked duplication, the 
mapped alignments were subjected to recalibration. Last, we per-
formed variant calling on the recalibrated alignment files and filtered 
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frequency is ≥0.01, and clinVar-annotated benign variants. EGFR vari-
ant calling was performed in the same practice as TCGA-GBM study (6).
Transcriptome data for lower-grade gliomas and GBM samples 
from the TCGA cohort (TCGA-LGG and TCGA-GBM) were 
downloaded using TCGABiolinks Bioconductor package via the 
National Cancer Institute Genomic Data Commons (6, 79). Gene 
expression matrix files for microarray dataset of Rembrandt and 
Gravendeel cohorts were downloaded through ArrayExpress 
(E-MTAB-3073) and Gene Expression Omnibus (GEO) (GSE16011), 
respectively (38, 80). Raw SRA files for published RNA-seq data with 
restricted access (table S1A) were fetched via SRA tools from the 
dbGAP with DAC approvals. Molecular subtypes of glioma samples 
from both in-house and published cohorts were determined by the 
GIE signatures (9). Expressional data of lncRNAs that were subjected 
to cross-tissue/tumor comparison were retrieved from the MiTran-
scriptome (81) by October 2017. The data used for prognostic analyses 
of RFX2 and TGIF1 were retrieved from expressional analysis of 
the Rembrandt and TCGA-GBM cohorts via Project Betastasis 
(http://betastasis.com). Patient stratification with SE gene signature 
was performed using Connectivity Map (82). Gene signature–based 
portraying of tissue cellular landscape was modeled by xCell (29).
To identify gene expression molecular subtype of our samples, we 
first combined and standardized our cohort in FPKM values with 
TCGA-GBM using ComBat (83). Once standardized, we extracted the 
centroid from the seminal study (9) and performed consensus clustering 
on the combined dataset. Our samples were then assigned the molecu-
lar subtype based on the highest similarity to the subtype centroid.
Statistical analysis
Unless otherwise stated, statistical significance was reported on the 
basis of either two-tailed Student’s t test (two-group comparison) or 
one-way analysis of variance (ANOVA) (multigroup comparison). 
Survival analysis was performed by log-rank test; Kaplan-Meier sur-
vival curves were plotted to show the survival of either patient groups 
or experimental groups. n.s., not significant; *P < 0.05, **P < 0.01, and 
***P < 0.001. Sample sizes were not predetermined statistically. Center 
values, error bars, and number of replicates are described in the cor-
responding figures and/or figure legends. Replicates represent (i) 
separate tumors in xenograft assays, (ii) individual animals in orthot-
opic tumor model, and (iii) independent biological repeats for 
in vitro assays.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/18/eabd4676/DC1
View/request a protocol for this paper from Bio-protocol.
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